Tinelli M, Percivalle E, Zambelli A, Grossi P, Maccabruni A
Istituto di Malattie Infettive di Pavia, IRCCS Policlinico S. Matteo, Italy.
Boll Ist Sieroter Milan. 1990 Jun;69(2):459-67.
The present study was set up to evaluate the efficacy of hyperimmune anti-CMV immunoglobulins (IVIG) in the prophylaxis of CMV infection in five patients suffering from dilatative myocardiopathy and submitted to hearth transplant. Different commercial IVIG were tested for anti-CMV neutralizing antibodies before administrated them to patients; the lots immunochemically prepared by PEG resulted to have the highest anti-CMV titer. IVIG treatment, when administered at high doses and at closes intervals of time, proved able to prevent and control CMV infections; when treatment was stopped, a primary infection occurred, easily controlled by short courses of DHPG. Even if our survey was limited to only five cases, it should be emphasized that after the suspension of the therapy, clinical symptoms were restricted to simple mononucleosis syndrome without organ disease. Furthermore it should be noted that during IVIG therapy no immediate or delayed adverse effects were observed.
本研究旨在评估高免疫抗巨细胞病毒免疫球蛋白（IVIG）对5例扩张型心肌病并接受心脏移植患者预防巨细胞病毒感染的疗效。在给患者使用不同的市售IVIG之前，检测其抗巨细胞病毒中和抗体；经聚乙二醇免疫化学制备的批次抗巨细胞病毒滴度最高。高剂量且短间隔时间给予IVIG治疗，证明能够预防和控制巨细胞病毒感染；当治疗停止时，发生了原发性感染，通过短疗程的膦甲酸钠很容易得到控制。即使我们的调查仅局限于5例病例，但应强调的是，治疗中止后，临床症状仅限于单纯的单核细胞增多症综合征，而无器官病变。此外，应注意在IVIG治疗期间未观察到即时或延迟的不良反应。
